The increased availability of data and recent advancements in artificial intelligence present the unprecedented opportunities in healthcare and major challenges for the patients, developers, providers and regulators. The novel deep learning and transfer learning techniques are turning any data about the person into medical data transforming simple facial pictures and videos into powerful sources of data for predictive analytics. Presently, the patients do not have control over the access privileges to their medical records and remain unaware of the true value of the data they have. In this paper, we provide an overview of the next-generation artificial intelligence and blockchain technologies and present innovative solutions that may be used to accelerate the biomedical research and enable patients with new tools to control and profit from their personal data as well with the incentives to undergo constant health monitoring. We introduce new concepts to appraise and evaluate personal records, including the combination-, time- and relationship-value of the data. We also present a roadmap for a blockchain-enabled decentralized personal health data ecosystem to enable novel approaches for drug discovery, biomarker development, and preventative healthcare. A secure and transparent distributed personal data marketplace utilizing blockchain and deep learning technologies may be able to resolve the challenges faced by the regulators and return the control over personal data including medical records back to the individuals.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5814166PMC
http://dx.doi.org/10.18632/oncotarget.22345DOI Listing

Publication Analysis

Top Keywords

artificial intelligence
12
personal data
12
data
10
next-generation artificial
8
accelerate biomedical
8
deep learning
8
medical records
8
personal
5
converging blockchain
4
blockchain next-generation
4

Similar Publications

Early Versus Delayed Antihypertensive Treatment After Acute Ischemic Stroke by Hypertension History.

Stroke

January 2025

Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, China. (X.X., X.L., Y.P., Yufei Wei, Y.J., M.W., J.J., X.M., Yilong Wang, Yongjun Wang, L.L.).

Background: We performed a prespecified subgroup analysis of the CATIS-2 trial (China Antihypertensive Trial in Acute Ischemic Stroke II) to compare the effect of early versus delayed antihypertensive treatment on death and disability in patients with and without medical history of hypertension.

Methods: CATIS-2 is a multicenter randomized clinical trial conducted in 106 hospitals in China. The trial randomized 4810 patients with acute ischemic stroke within 24 to 48 hours of symptom onset and elevated systolic blood pressure between 140 and <220 mm Hg to receive antihypertensive treatment immediately after randomization or to discontinue antihypertensive medications for 7 days and then receive treatment on day 8.

View Article and Find Full Text PDF

Severity of metabolic derangement predicts survival after out-of-hospital cardiac arrest and the likelihood of benefiting from extracorporeal life support.

Emergencias

December 2024

Department of Emergency Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seúl, República de Corea. Department of Digital Health, SAIHST, Sungkyunkwan University, Seúl, República de Corea.

Objective: To develop a Metabolic Derangement Score (MDS) based on parameters available after initial testing and assess the score's ability to predict survival after out-of hospital cardiac arrest (OHCA) and the likely usefulness of extracorporeal life support (ECLS).

Methods: A total of 5100 cases in the Korean Cardiac Arrest Research Consortium registry were included. Patients' mean age was 67 years, and 69% were men.

View Article and Find Full Text PDF

Background: Diabetic kidney disease (DKD) is one of the typical complications of type 2 diabetes (T2D), with approximately 10 % of DKD patients experiencing a Rapid decline (RD) in kidney function. RD leads to an increased risk of poor outcomes such as the need for dialysis. Albuminuria is a known kidney damage biomarker for DKD, yet RD cases do not always show changes in albuminuria, and the exact mechanism of RD remains unclear.

View Article and Find Full Text PDF

Developing Mobile Health Applications for Inflammatory Bowel Disease: A Systematic Review of Features and Technologies.

Middle East J Dig Dis

October 2024

Department of Health Information Technology, Ferdows Faculty of Medical Sciences, Birjand University of Medical Sciences, Birjand, Iran.

Background: Patients with inflammatory bowel disease (IBD) require lifelong treatment, which significantly impacts their quality of life. Self-management of this disease is an effective factor in managing chronic conditions and improving patients' quality of life. The use of mobile applications is a novel approach to providing self-management models and healthcare services for patients with IBD.

View Article and Find Full Text PDF

KSA is transforming its healthcare system by developing and implementing Clinical Practice Guidelines (CPGs), a tool designed to improve patient outcomes, standardize care, and facilitate evidence-based decision-making. CPGs are crucial in addressing healthcare disparities, thereby promoting health equity and patient experience. They are integral to KSA's healthcare transformation agenda.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!